Immunovia Expands its Lung Cancer Program Based on Encouraging Results from the Current Discovery Study
LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) today announced that the results of the current study in lung cancer strongly supports an expansion into the next stage in the discovery process. With the recent capital raise, Immunovia is fully financed to expand the discovery process in lung cancer. The next step in the lung cancer program expansion is a study of a larger cohort of fresh lung cancer samples that best mirrors the commercial environment. Lung cancer is by far the leading cause of cancer death among both men and women. Each year, more people die of lung cancer than of